metrizamide
Trade name: amipaque
Small moleculeapproved
Approved
Aug 23, 1978
Metrizamide is a glucosamine derivative of metrazoic acid, used as a contrast medium for myelography. Metrizamide is no longer marketed in the US. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1970s
- Aug 23, 1978
General Electric — Earliest FDA Approval
- Aug 23, 1978
General Electric — NDA Secondary Org
- Aug 23, 1978
General Electric — NDA Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedPriority reviewAug 23, 1978
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)Nc1c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c(I)c(N(C)C(C)=O)c1I- Mol. weight
- 789.1 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL462394 ↗
- WikipediaMetrizamide ↗
- NCATSRHH3W8F1CO ↗
- ChEMBLCHEMBL1200889 ↗
Also known as
- amipaque
- amipaque
- amipaque
- amipaque
- metrizamide
- metrizamide
- metrizamide
- metrizamide
- metrizamide
- metrizamide
- metrizamide
- metrizamide
- metrizamide
- metrizamide
- telebrix
- win-39103
- win-39103
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| General Electric | For profit | NDA2 | Aug 23, 1978 |
| General Electric | For profit | NDA | Aug 23, 1978 |